Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | QDPR | P09417 | 2/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18113487 | 0.99 | HTR2C (0.49) | SIGMAR1HTR2CQDPRWNT3APRMT5 | |
| SCHEMBL12193536 | 0.84 | SIGMAR1 (0.61) | SIGMAR1HTR2CQDPRHRH3GRM5 | |
| SCHEMBL171238 | 0.84 | SIGMAR1 (0.62) | SIGMAR1HTR2CQDPRWNT3APRMT5 | |
| Hydrochloric Acid SCHEMBL18113481 | 0.83 | HTR2C (0.62) | SIGMAR1HTR2CQDPRGRM5 | |
| SCHEMBL13490517 | 0.79 | SIGMAR1 (0.66) | SIGMAR1HTR2CQDPRWNT3AHRH3 | |
| SCHEMBL171420 | 0.79 | HTR2C (0.66) | SIGMAR1HTR2CQDPRWNT3APRMT5 | |
| SCHEMBL12374234 | 0.79 | HTR2C (0.39) | SIGMAR1HTR2CQDPRWNT3AHRH3 | |
| SCHEMBL30454304 | 0.78 | SIGMAR1 (0.56) | SIGMAR1HTR2CQDPRGRM5 | |
| SCHEMBL169400 | 0.78 | SIGMAR1 (0.56) | SIGMAR1HTR2CQDPRGRM5 | |
| Hydrochloric Acid SCHEMBL2275244 | 0.78 | HTR2C (0.40) | SIGMAR1HTR2CQDPRWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277690-B1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| WO-2016161160-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2008156739-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1966151-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | SIGMAR1 1543/4885HTR2C 4139/4885QDPR 546/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | SIGMAR1 1454/4885HTR2C 3899/4885QDPR 441/4885 |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | SIGMAR1 2013/4885HTR2C 2823/4885QDPR 2060/4885 |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | SIGMAR1 2013/4885HTR2C 2823/4885QDPR 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.